Navigation Links
Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the fourth quarter and year ended December 31, 2010.

"2010 was a year of significant progress for Verenium. Even as we completed the complex process of refocusing on our core enzymes business, we were able to achieve or exceed our growth targets for the business," said James E. Levine, President and Chief Executive Officer Designate of Verenium. "Based on the solid performance of our commercial products as well as the interest we've had from potential partners for our pipeline products, I am very enthusiastic about the many opportunities ahead. I expect 2011 will be an important year for Verenium in which we will focus on achieving our corporate goals which we believe will continue to position Verenium as a leading industrial enzymes company."

Company HighlightsDuring 2010 Verenium has made significant progress on both the operational and financial fronts.  Most recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Achieved a 25% increase in full year 2010 gross profit from Phyzyme sales over the same period in 2009 due to strong demand for Phyzyme phytase.

  • Grain Processing

  • Grew full year 2010 revenues from the Company's grain processing enzymes, including Fuelzyme, Deltazym GA L-E5, Veretase and Xylathin, by 38% over the same period in 2009; and
  • Grain processing has grown to represent 27% of 2010 product revenues.

  • Oilseed Processing

  • Increased Purifine® PLC plant count from one in 2009 to four at the end of 2010 and currently have five plants in the process of implementation; and
  • Announced joint marketing agreement with a second global engineering partner, Desmet Ballestra, for Purifine® PLC, and extended the partnership agreement with Alfa Laval.

  • Manufacturing

  • Expanded committed fermentation capacity at Fermic, the Company's contract manufacturing partner, and launched a manufacturing improvement program to expand downstream capacity, increase manufacturing efficiency and improve overall stability of manufacturing processes.

  • Corporate/Financial:

  • Increased total product revenue by 15% to $50.4 million for the year ended December 31, 2010, achieving 2010 guidance range of $48 to $54 million;
  • Increased 2010 year end product gross profit by 16% to $18.6 million, exceeding 2010 annual guidance of $16 to $18 million;
  • Increased full year non Phyzyme revenue from 25% in 2009 to 35% in 2010 through increasing sales of Company's newer enzymes including Fuelzyme, Xylathin, Veretase, Deltazym GA L-E5 and Purifine; and
  • Ended the quarter and year with unrestricted cash and cash equivalents totaling $87.9 million and convertible notes outstanding of $74.7 million.

  • "We ended 2010 with a more flexible financial structure and better positioned to invest strategically and grow the industrial enzymes business," said Jeffrey G. Black, Senior Vice President and Chief Financial Officer Designate.  "In 2011 we will look to further solidify our capital structure and create a clear path to profitability through a combination of revenue and gross margin growth, pipeline development, manufacturing improvements, and strategic partnerships."

    Financial ResultsIn the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP.Revenues

    Revenues for the periods ended December 31, 2010 and 2009 were as follows (in thousands): Three Months Ended December 31,Year Ended December 31,2010200920102009Revenues:Animal Health and Nutrition

    32,781Grain Processing

    3,8342,72813,4399,744All other products

    1,3812004,3241,431Total product

    13,26611,86250,35143,956Collaborative and grant

    3311,4941,7224,863Total revenues

    48,819Total revenues for the year ended December 31, 2010 increased 7% to $52.1 million from $48.8 million in the prior year, with product revenues representing 90% or more of total revenues in both periods. Product revenues for the year ended December 31, 2010 increased 15% to $50.4 million from $44.0 million in the prior year, primarily due to an increase in Phyzyme profit share from Danisco, as well as an increase in revenues from grain processing enzymes, Fuelzyme, Veretase, Deltazym GA L-E5 and Xylathin, which continued to gain traction in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. Product revenue from non-Phyzyme products as a percentage of total product revenue increased to 35% for the year ended December 31, 2010 compared to 25% in the prior year.

    Product Gross Profit

    Product gross profit for the year ended December 31, 2010 increased 16% to $18.6 million from $16.0 million in the prior year, primarily due to improved fixed cost leverage on higher revenue, partially offset by the impact of manufacturing constraints compared to the prior year, resulting from the challenges of satisfying increased demand for our products and expanded product mix.

    Operating Expenses (excluding cost of product revenue)

    Excluding cost of product revenues, total operating expenses related to continuing operations decreased to $33.9 million (including share-based compensation of $1.1 million) for the year ended December 31, 2010 from $35.3 million (including share-based compensation of $4.7 million) for the same period in the prior year.  Excluding the impact of share-based compensation, total operating expenses increased $2.2 million primarily due to bonus payments expensed during the year ended December 31, 2010, for which there was no corresponding expense in 2009.

    Operating Loss from Continuing Operations

    Operating loss from continuing operations for the year ended December 31, 2010 was $13.5 million compared to $14.5 million for the same period in 2009, reflective of the increase in product gross margin and a decrease in selling, general & administrative expenses. Excluding the impact of share-based compensation, total operating loss from continuing operations increased $2.6 million primarily due to bonus payments expensed during the year ended December 31, 2010, for which there was no corresponding expense in 2009.

    Net Loss from Continuing Operations

    Net loss from continuing operations for the year ended December 31, 2010 was $14.2 million compared to a net loss of $6.4 million for the same period in 2009, on a GAAP accounting basis. Adjusted for the impact of non-cash items, the Company's non-GAAP pro-forma net loss from continuing operations for the year ended December 31, 2010 was $21.0 million compared to $24.6 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

    Financial Guidance for 2011Verenium also updated 2011 financial guidance for R&D and SG&A expenses.  The Company re-allocated the accounting of certain expenses from R&D to SG&A, leaving the total level of operating expenses unchanged at $33 to $37 million.

  • Revenue: $55 to $60 million
  • Product Gross Profit: $21 to $24 million
  • R&D: $10 to $12 million
  • SG&A: $23 to $25 million

  • Planned capital investments for the commercial business, including manufacturing debottlenecking, are expected to be between $4 and $6 million.  In addition, the Company expects to spend up to $10 million to build out a new San Diego, CA facility over the next two years and is exploring opportunities for spreading the capital expenditure over a longer period of time.

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

    Contacts:Kelly Lindenboom

    Vice President, Corporate Communications


    Sarah Carmody

    Manager, Corporate Communications


    sarah.carmody@verenium.comVerenium CorporationConsolidated Statements of Operations(unaudited, in thousands, except per share amounts)Three Months Ended
    December 31, Year Ended
    December 31, 2010200920102009Revenues:   Product

    43,956   Collaborative and grant

    3311,4941,7224,863Total revenue

    13,59713,35652,07348,819Operating expenses:   Cost of product revenue

    8,5367,44731,71527,929Product Gross Profit

    4,7304,41518,63616,027Product Gross Margin

    36%37%37%36%   Research and development

    2,0681,0206,1985,829   Selling, general and administrative

    6,1944,64927,66229,520Total operating expenses

    16,79813,11665,57563,278Operating income (loss) from continuing operations

    (3,201)240(13,502)(14,459)Other Income and Expense:

      Interest and other expense, net

    (1,301)(1,125)(7,481)(10,105)   Loss on debt extinguishment

    ----(3,384)--   Gain on debt extinguishment upon conversion

    --3175988,946   Gain on amendment of 2008 Notes

    ------3,977   Gain (loss) on net change in fair value of derivative assets and liabilities

    872199(145)5,277Total other income (expense), net

    (429)(609)(10,412)8,095Loss from continuing operations before income taxes

    (3,630)(369)(23,914)(6,364)Income tax benefit

    1,820--9,748--Net loss from continuing operations

    (1,810)(369)(14,166)(6,364)Discontinued Operations:

      Net income (loss) from discontinued operations, net of income taxes

    (1,490)(11,438)8,816(49,876)Less: Loss attributed to noncontrolling interests in consolidated entities – discontinued operations

    --8,84925,28334,349Net income (loss) attributed to Verenium

    (21,891)Basic and diluted net income (loss) per share:

    Continuing Operations

    (0.75)Discontinued Operations

    (5.89)Net income (loss) attributed to Verenium

    (2.58)Shares used in computing basic and diluted net income (loss) per share

    12,59111,49312,3218,470Verenium CorporationCondensed Consolidated Balance Sheet Data(unaudited, in thousands)December 31,December 31,20102009Cash and cash equivalents

    24,844Accounts receivable, net

    6,7086,558Inventory, net

    5,3162,586Other current assets  

    2,6942,500Restricted cash

    5,00010,400Property and equipment, net  

    3,1344,169Other noncurrent assets  

    9762,020Assets of discontinued operations

    --114,845Total assets  

    7,922Current liabilities, excluding deferred revenue and liabilities of discontinued operations

    ,523Deferred revenue, current  

    894895Convertible notes, at carrying value (face value of $74.7 million at December 31, 2010 and $97.9 million at December 31, 2009)

    88,011105,756Other long term liabilities  

    1,2161,734Liabilities of discontinued operations  

    1,61718,812Stockholders' equity  

    3,17030,202Total liabilities, noncontrolling interests and stockholders' equity  

    7,922Verenium CorporationUnaudited Supplemental and Non-GAAP Pro Forma Financial Information (in thousands, except per share amounts)The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three months and years ended December 31, 2010 and 2009, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business. Non-GAAP Pro Forma Net Loss From Continuing OperationsThree Months Ended

    December 31,Year Ended

    December 31,2010200920102009Net loss from continuing operations

    (6,364)   Adjustments:  Income tax benefit

    (1,820)--(9,748)--Loss on debt extinguishment

    ----3,384--Gain on debt extinguishment upon conversion

    --(317)(598)(8,946)Gain on amendment of 2008 Notes

    ------(3,977)(Gain) loss on net change in fair value of derivative assets and liabilities

    (872)(199)145(5,277)   Non-GAAP pro forma net loss from continuing operations  

    (24,564)Non-GAAP pro forma net loss from continuing operations per share  


    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Verenium Announces 2010 Business Update and Outlook for 2011
    2. Verenium Announces Changes in Senior Management
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    (Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
    (Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
    (Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
    (Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
    Breaking Medicine News(10 mins):